Clinical trials: Drug Poisoning
Drug-Induced Liver Injury
Efficacy and Safety Study of Magnesium Isoglycyrrhizinate Injection in Subjects With Acute Drug-induced Liver Injury
The purpose of this study is to investigate the safety, effective dosage and treatment of Magnesium Isolycyrrhizinate Injection to cure the acute drug-induced liver injury compared with the Tiopronin Injection.
- Trial name
- NCT02734966
- Testing
- Magnesium Isoglycyrrhizinate Injection 100mg OD, Magnesium Isoglycyrrhizinate Injection 200mg OD, Tiopronin Injection
- Where
- 8 sites in China
- Volunteers
- 174 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Sepsis, Critical Illness
Optimizing Vancomycin Therapy in Children
The purpose of Opt Vanc is to evaluate the feasibility of Bayesian dose adaptation, based on a previously-developed population pharmacokinetic (PK) model and a single optimally timed PK sample, to predict vancomycin area under…
- Conditions
- Sepsis, Critical Illness, Infections, Drug Toxicity
- Trial name
- Opt Vanc (NCT05691309)
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Children's Hospital of Philadelphia
Drug-induced Liver Injury, Gut Microbiota
Alterations of Gut Microbiota and Serum Biochemical Markers in DILI Patients
Drug-induced liver injury is a leading cause of acute liver failure worldwide and one of the least understood areas in hepatology research.
- Conditions
- Drug-induced Liver Injury, Gut Microbiota, Biochemical Markers
- Trial name
- NCT05465642
- Testing
- Collect stool and blood samples from patients
- Where
- China
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Hepatitis, Toxic
Cholestatic Drug-induced Liver Injury
Cholestatic drug-induced liver injury (DILI) is the severe form of DILI with a grave outcome. Drug-metabolizing enzymes play an important role in the metabolism of drugs.
- Trial name
- DILI (NCT01141322)
- Testing
- Ursodeoxycholic Acid
- Where
- Taiwan
- Volunteers
- 180 people
- Sponsor
- Taipei Veterans General Hospital, Taiwan
Quality of Life, Infection
Impact of AferBio® on Quality of Life and Chemotherapy Toxicity in Lung Cancer Patients
The AFERBIO study will evaluates safety and potential benefit of AferBio® in patients with non-small cell lung cancer undergoing at least a second-line palliative monochemotherapy.
- Conditions
- Quality of Life, Infection, Drug Toxicity
- Trial name
- AFERBIO (NCT03469063)
- Testing
- AferBio
- Where
- Brazil
- Volunteers
- 104 people
- Sponsor
- Barretos Cancer Hospital
Diffuse Large B-Cell Lymphoma, Drug Toxicity
Reduction of MTX Levels After Glucarpidase Treatment in DLBCL Patients at Risk of CNS
Diffuse large B-cell lymphoma (DLBCL) is an aggressive subset of non-Hodgkin's lymphoma (NHL). Central nervous system (CNS) involvement in patients with NHL is a serious complication.
- Trial name
- NCT05022797
- Testing
- Glucarpidase 1000 UNT [Voraxaze]
- Where
- 2 sites in Spain
- Volunteers
- 3 people
- Sponsor
- Fundacion CRIS de Investigación para Vencer el Cáncer
Drug Toxicity
Antidote for Valproic Acid Toxicity: a New Indication for Meropenem Antibiotic.
Acute Valproic acid (VPA) toxicity is an emergency condition which may commonly present with central nervous system (CNS) depression(5).
- Trial name
- NCT04671589
- Testing
- Meropenem Injection
- Where
- Egypt
- Volunteers
- 48 people
- Sponsor
- Mabaret Al-Asafara Hospitals
Drug Overdose, Overdose of Beta-adrenergic Blocking Drug
Glucagon's Cardiovascular Effects With and Without Beta-blocker-induced Cardioinhibition
This trial investigates effects of a glucagon bolus injection on heart rate, blood pressure and cardiac output during beta-blocker-induced cardiodepression.
- Trial name
- GLUCAGON (NCT03533179)
- Testing
- Glucagon, Esmolol, Physiologic saline - glucagon dummy
- Where
- Denmark
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University Hospital Bispebjerg and Frederiksberg
Infection, Bacterial
Plasma Concentrations of Amoxicillin Administered in High-doses During the First Week of Treatment (MAX-AMOX)
Amoxicillin is the most prescribed antibiotic in France. High dose intravenous amoxicillin, (dosage greater than or equal to 150 mg / kg / day or 12 g per day for patients over 80 kg) is used in the treatment, in particular, of…
- Trial name
- MAX-AMOX (NCT04070469)
- Testing
- Amoxicillin
- Where
- France
- Volunteers
- 142 people
- Sponsor
- University Hospital, Clermont-Ferrand
Acute Liver Failure, Acute Liver Injury, Drug Induced
miroliverELAP® for the Treatment of Acute Liver Failure: A Phase 1 Trial
The clinical trial will assess the safety of miroliverELAP for the treatment of acute liver failure, severe acute alcohol-associated hepatitis, or acute on chronic liver failure.
- Conditions
- Acute Liver Failure, Acute Liver Injury, Drug Induced, Acute on Chronic Liver Failure (ACLF), Acute Alcoholic Hepatitis
- Trial name
- NCT06285253
- Testing
- miroliverELAP treatment
- Where
- 8 sites in United States
- Volunteers
- 10 people
- Sponsor
- Miromatrix Medical Inc.
Cancer, Drug Toxicity
Atrial Fibrillation in Active Cancer Patients
Atrial fibrillation is a common complication of both cancer and anticancer drugs but the consequences of such events remain poorly known and are not adressed in both phase III oncological trials and cardiological guidelines.
- Conditions
- Cancer, Drug Toxicity, Atrial Fibrillation, Cardiovascular Complication
- Trial name
- AFIB-CANCER (NCT04696081)
- Testing
- occurence of atrial fibrillation
- Where
- France
- Volunteers
- 1,000 people
- Sponsor
- University Hospital, Caen
HIV
Economic, Clinical and Quality of Life Assessment in Patients on Antiretroviral Therapy
The purpose of this study is to compare clinical, economical and quality of life (QOL) outcomes in patients living with HIV on zidovudine/stavudine regimen and tenofovir regimen. This study will be an unblinded randomized trial.
- Trial name
- NCT01694017
- Testing
- Tenofovir, Zidovudine
- Where
- India
- Volunteers
- 68 people
- Sponsor
- Tufts University
Enhanced Child-safety Packaging
Efficacy of Flow Restrictors in Limiting Access of Liquid Medicines by Young Children
This study aimed to assess whether adding flow restrictors, adapters added to the neck of a bottle to limit the release of liquid, affects the proportion of preschool-aged children who can access liquid bottle contents, the…
- Trial name
- NCT06938620
- Testing
- Bottle with a flow restrictor, Control bottle
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention
Drug-Induced Liver Injury
Surveillance for Early Liver Injuries Caused by Runzao Zhiyang Capsule.
This is a prospective registry study to surveil early liver injuries caused by Runzao Zhiyang Capsule (RZZY Capsule) through a non-intervention observational way.
- Trial name
- NCT03091218
- Where
- China
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Beijing 302 Hospital
Methadone Toxicity, Methadone Overdose
Methadone Dose Monitoring With a Remote Medication Monitor
Proof of concept: Pilot Study A Pilot, proof of concept, observational study with a long-term goal to develop a minimally invasive wearable Remote Medication Monitor (RMM) that provides continuous, real-time data on methadone…
- Conditions
- Methadone Toxicity, Methadone Overdose, Pain, Chronic, Drug Metabolism, Poor, CYP2D6-Related
- Trial name
- NCT06837571
- Testing
- Measurement of Methadone in the Interstitial Fluid (ISF) before and after prescribed dose taken ex vivo, Measurement of Methadone in the Interstitial Fluid before and after prescribed dose taken in vivo, ISF Extraction Device 2
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Cari Health Inc.
Akathisia, Drug-Induced, Dyskinesia, Drug-Induced
Study of Preladenant for the Treatment of Antipsychotic Induced Movement Disorders in Participants With Schizophrenia (Study P04628)
This study was designed to determine if preladenant (SCH 420814, MK-3814) can reduce drug-induced involuntary movements in participants with schizophrenia or schizoaffective disorder.
- Conditions
- Akathisia, Drug-Induced, Dyskinesia, Drug-Induced, Parkinsonian Disorders
- Trial name
- NCT00686699
- Testing
- Preladenant
- Volunteers
- 11 people
- Sponsor
- Merck Sharp & Dohme LLC
Fluorosis, Dental, Fluorosis
Design of a Multicomponent Intervention to Reduce the Risk of Exposure Fluorine
Introduction Systemic exposure to fluoride is a significant challenge for global public health; this is because although fluoride prevents dental caries, prolonged exposure to high concentrations can cause adverse effects on…
- Trial name
- NCT07359937
- Testing
- multicomponent intervention, Conventional intervention
- Where
- Colombia
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Universidad Antonio Nariño
Chemotherapeutic Agent Toxicity, Lymphoma
Methotrexate, Glucarpidase, and Leucovorin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma
RATIONALE: Drugs used in chemotherapy, such as methotrexate and leucovorin, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Chemotherapeutic Agent Toxicity, Lymphoma, Mucositis, Neurotoxicity
- Trial name
- NCT00727831
- Testing
- glucarpidase, leucovorin calcium, methotrexate
- Where
- 2 sites in United Kingdom
- Volunteers
- 4 people
- Sponsor
- University College, London
Schizophrenia
Transcutaneous Non-invasive Vagus Nerve Stimulation (t-VNS) in the Treatment of Schizophrenia
Randomized, controlled, double-blind, two-armed clinical investigation to show the efficacy and safety of transcutaneous vagus nerve stimulation (t-VNS), applied at the left auricle, in schizophrenia.
- Trial name
- 02VNS2009 (NCT01176721)
- Testing
- t-VNS verum
- Where
- 2 sites in Germany
- Volunteers
- 20 people
- Sponsor
- cerbomed GmbH
Melanoma, Neoplasm Metastasis
PegIntron Versus IntronA in CMAJCC Stage II (EADO 2001/CMII Trial)
Melanoma with a tumor thickness >= 1.5mm without clinically detectable nodes represents an increasing population with relapse rate of more than 50%.
- Trial name
- EADO (NCT00221702)
- Testing
- PegIntron, intron A
- Where
- France
- Volunteers
- 898 people
- Sponsor
- University Hospital, Bordeaux